Jakob Schöllhammer Knudsen

Jakob Schöllhammer Knudsen

Auto-generated profile, based on publicly available information

Jakob Schöllhammer Knudsen

Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2020 in Pancreatology
Verified
Journal Article
Closed access
JKJakob Schöllhammer Knudsen
Jakob Schöllhammer Knudsen
UHUffe Heide-Jørgensen
Uffe Heide-Jørgensen
FMFrank Viborg Mortensen
Frank Viborg Mortensen
HSHenrik Toft Sørensen
Henrik Toft Sørensen
VEVera Ehrenstein
Vera Ehrenstein

4 March 2020 in PLOS ONE
Verified
Journal Article
Open access
PDF file
JKJakob S. Knudsen
Jakob S. Knudsen
LBLisbeth M. Baggesen
Lisbeth M. Baggesen
MLMaria Lajer
Maria Lajer
LNLarisa Nurkanovic
Larisa Nurkanovic
AUAnastasia Ustyugova
Anastasia Ustyugova
RTReimar W. Thomsen
Reimar W. Thomsen
We investigated changes in clinical characteristics of SGLT2i and GLP-1RA real-world initiators in Denmark before/after landmark cardiovascular outcome trials. We compared first-time SGLT2i (25,070) and GLP-1RA (14,671) initiators to initiators of DPP-4i (n = 34,079), a class without proven cardiovascular benefits. We used linked population-based healthcare data to examine initiation incidence, medication patterns, and pre-existing atherosclerotic cardiovascular disease (ASCVD) during 2014–2017. Nationwide incidence of SGLT2i initiators increased 3.6-fold (53/100,000 to 172/100,000 per year) vs. a 1.5-fold increase for GLP-1RA. DPP-4i initiation remained stable. From the end of 2015, SGLT2i was increasingly used as 2nd-line therapy, while medication patterns were much more stable for GLP-1RA. Among SGLT2i users, ASCVD increased slightly from 28% to 30%; age- and gender-adj. prevalence ratio (aPR) = 1.03 (95% CI:0.97–1.10). In contrast, among GLP-1RA initiators, baseline ASCVD declined from 29% to 27% (aPR: 0.90 (95% CI:0.84–0.97)), and in DPP-4i initiators from 31% to 29% (aPR: 0.91 (95% CI:0.88–0.96)). Following the EMPA-REG OUTCOME trial in 2015, SGLT2i have become increasingly used as 2nd-line treatment in everyday clinical practice, with only minor increases in patient proportions with ASCVD. For GLP-1RA, we observed more stable therapy lines and slightly decreasing ASCVD in new users despite the LEADER trial.

5 July 2017 in British Journal of Pharmacology
Verified
Journal Article
Closed access
PDF file
MLMorten Laursen
Morten Laursen
LBLilliana Beck
Lilliana Beck
JKJan Kehler
Jan Kehler
CCClaus Tornby Christoffersen
Claus Tornby Christoffersen
CBChristoffer Bundgaard
Christoffer Bundgaard
Ulf SimonsenUlf Simonsen
Ulf Simonsen

2 November 2020 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Open access
PDF file
KFKristian Løkke Funck
Kristian Løkke Funck
JKJakob Schöllhammer Knudsen
Jakob Schöllhammer Knudsen
THTroels Krarup Hansen
Troels Krarup Hansen
RTReimar Wernich Thomsen
Reimar Wernich Thomsen
EGErik Lerkevang Grove
Erik Lerkevang Grove
Aims: To investigate temporal trends in time to initiation of sodium‐glucose co‐transporter‐2 inhibitors and glucagon‐like peptide 1 analogues (cardioprotective glucose‐lowering drugs [GLDs]) in patients with a new dual diagnosis of type 2 diabetes (T2DM) and cardiovascular disease (CVD). Materials and methods: In a cohort study, we identified patients with a new dual diagnosis of T2DM and CVD using linked healthcare data from nationwide registries on drug prescriptions and diagnosis codes. For each calendar year between 2012 and 2018, we examined time to initiation and cumulative user proportions (CUPs) for cardioprotective GLD use 1 and 2 years after the dual diagnosis. Results: Among all individuals living in Denmark in the period 2012 to 2018, 41 733 patients with a new dual diagnosis of T2DM and CVD were identified (median [interquartile range] age 71 [64–79] years, 61% male, and 57% with CVD as the latest diagnosis). Incidence curve slopes and 1‐ and 2‐year CUPs for cardioprotective GLDs increased during the study period (1‐year CUP 4.0%, 95% confidence interval [CI] 3.6–4.5) in 2012 to 14.7, 95% CI 13.7–15.7, in 2018; 2‐year CUP 5.5, 95% CI 5.0–6.1, in 2012 to 16.7, 95% CI 15.8–17.7, in 2017). T2DM patients with CVD as the second (latest) diagnosis had higher 1‐year CUPs than CVD patients with T2DM as the latest diagnosis: 2012: 7.0 (95% CI 6.2–8.0) versus 1.4 (95% CI 1.0–1.8); 2018: 18.1 (95% CI 16.8–19.6) versus 10.0 (95% CI 8.8‐11.3). Conclusions: In patients with T2DM and CVD, the incidence of cardioprotective GLD initiation increased between 2012 and 2018, however, within 2 years of dual diagnosis, it remained low.

11 August 2021 in Diabetes Care
Verified
Journal Article
Open access
PDF file
CGChristine Gyldenkerne
Christine Gyldenkerne
JKJakob S. Knudsen
Jakob S. Knudsen
KOKevin K.W. Olesen
Kevin K.W. Olesen
Henrik Toft SørensenHenrik Toft Sørensen
Henrik Toft Sørensen
HBHans Erik Bøtker
Hans Erik Bøtker
MMMichael Maeng
Michael Maeng
OBJECTIVE: Trends in cardiac risk and death have not been examined in patients with incident type 2 diabetes and no prior cardiovascular disease. Therefore, we aimed to examine trends in cardiac risk and death in relation to the use of prophylactic cardiovascular medications in patients with incident type 2 diabetes without prior cardiovascular disease. RESEARCH DESIGN AND METHODS: In this population-based cohort study, we included patients with incident type 2 diabetes between 1996 and 2011 through national health registries. Each patient was matched by age and sex with up to five individuals without diabetes from the general population. All individuals were followed for 7 years. RESULTS: We identified 209,311 patients with incident diabetes. From 1996–1999 to 2008–2011, the 7-year risk of myocardial infarction decreased from 6.9 to 2.8% (adjusted hazard ratio [aHR] 0.39 [95% CI 0.37–0.42]), cardiac death from 7.1 to 1.6% (aHR 0.23 [95% CI 0.21–0.24]), and all-cause death from 28.9 to 16.8% (aHR 0.68 [95% CI 0.66–0.69]). Compared with the general population, 7-year risk differences decreased from 3.3 to 0.8% for myocardial infarction, from 2.7 to 0.5% for cardiac death, and from 10.6 to 6.0% for all-cause death. Use of cardiovascular medications within ±1 year of diabetes diagnosis, especially statins (5% of users in 1996–1999 vs. 60% in 2008–2011), increased during the study period. CONCLUSIONS: From 1996 to 2011, Danish patients with incident type 2 diabetes and no prior cardiovascular disease experienced major reductions in cardiac risk and mortality. The risk reductions coincided with increased use of prophylactic cardiovascular medications.

7 November 2018 in British Journal of Pharmacology
Verified
Journal Article
Closed access
PDF file
MBMaj Bangshaab
Maj Bangshaab
AGAlejandro Gutierrez
Alejandro Gutierrez
KHKhiem Dinh Huynh
Khiem Dinh Huynh
JKJakob Schöllhammer Knudsen
Jakob Schöllhammer Knudsen
Daniel Dias Rufino ArcanjoDaniel Dias Rufino Arcanjo
Daniel Dias Rufino Arcanjo
Ulf SimonsenUlf Simonsen
Ulf Simonsen